SEARCH RESULTS

UbiMobility 2017: Business France and Bpifrance Accelerate 8 Innovative Startups and SMEs in the US Autonomous Vehicle Sector

PRESS RELEASE - 04-avr.-2017 16:58:22
  UbiMobility 2017: Business France and Bpifrance Accelerate 8 Innovative Startups and SMEs in the US Autonomous Vehicle Sector - 8 startups selected by a jury of major actors in the connected and autonomous vehicle space in the United States - A 10-month acceleration program and 2 week immersion program in the automotive ecosystems of Detroit and San Francisco - It’s third edition underway, UbiMobility 2017 boasts two successful editions in its past March 13th, Intel announced the acquisition of the Israeli company Mobileye which specializes in driving assistance systems for 15 $ billion. The announcement boosts the race for new technologies in the autonomous and connected vehicle industries in the United States and opens up a major market for specialized startups.   Today, Business France and Bpifrance unveiled the 8 startups selected to participate in the 3rd edition of UbiMobility, an acceleration program in the connected and autonomous vehicle sector in the United States.    Beginning on June 3rd, the eight selected French companies will begin an intensive two-week immersion program presenting their technologies and developing partnerships with major U.S. players in the industry. UbiMobility will take the delegation to two major ecosystems in the automotive industry – Detroit/Ann Arbor and San Francisco / Silicon Valley.   Additionally, these eight startups will be part of a 10-month program where Business France will provide professional support, and guidance, in order to foster the relationships established between the French and American companies. For the third edition of UbiMobility, a jury comprised of representatives from key U.S. automotive companies selected the 8 startups from a pool of 20 pre-selected companies. The selected startups offer advanced technologies in the key areas of the connected and autonomous vehicles including advanced driving and safety, facial and vocal recognition, driver behavior and interaction, vehicle connectivity and software validation.   Supported by Bpifrance in their innovation efforts, most, if not all of these companies have made the United States their target market. Designed as a program to accelerate their integration onto the U.S. automotive industry, UbiMobility provides the opportunity for these eight companies to present their companies to the automakers, suppliers, VC, and research communities.   On site, each of them will benefit from personalized support from Business France. The goal is to build a lasting relationship with potential customers and strategic partners in the North American market.   The companies will receive coaching to adapt their message to the U.S. market. They will participate in targeted events bringing together the diverse members of the automotive / mobility communities and will benefit from a program of personalized BtoB meetings. While in the U.S., the UbiMobility delegation will meet with each jury member* and their autonomous and connected vehicle teams, including:   Ford Silicon Valley, Delphi, FCA, Valeo North America, The University of Michigan, WardsAuto, Magna International, The University of California – Berkeley and the Boston Consulting Group.    In addition to the jury, past meetings have included new automotive manufacturers and mobility companies such as Uber, Tesla, Faraday Future, Google, NVIDIA, venture capitalist firms and research institutions. This unique mixture of complete immersion and long-term professional support has demonstrated the program’s effectiveness of introducing French innovation onto the U.S. market.   Results from the first 2 editions of UbiMobility: - Coaching and development of 16 innovative startups and SMEs - 11 companies’ presence and expansion to the U.S. market (Actia, Vulog, Navya, Trust In Soft, - Roadeyes, Kronosafe, Optis, ESI Group, Prove & Run, Pradeo, Arkamys)   - Contracts or agreements signed for 75% of them (Actia, Vulog, Navya, Trust In Soft, Roadeyes, - Intempora, Krono-Safe, Optis, ESI Group, Prove & Run, Akoustic Arts, YoGoKo)   - 47.5 million euros raised for their international development   The stakes are high. Auto manufacturers, suppliers, Silicon Valley firms and local authorities are heavily invested in the development of autonomous and connected vehicles. The University of Michigan has developed Mcity, a unique test facility in the suburb of Ann Arbor, designed to test autonomous vehicles in real-life conditions. Thanks to UbiMobility, the 100 % electric and autonomous shuttle Navya was selected to be a part of the Mcity program. The integration of advanced technologies influences the emergence and deployment of the autonomous and semi-autonomous vehicle. According to the Boston Consulting Group, a majority of urban consumers are mostly in favor of autonomous cars (58% in France, 52% in the United States). This new mode of transportation has considerable perceived benefits (parking, the possibility using travel time to accomplish tasks ...). Its generalization should have a major impact on mobility solutions. Nevertheless, this will only be possible if the safety of the user is guaranteed. As Hadi Zablit, BCG’s Senior Partner and Managing Director Paris, points out, security remains a concern for a significant portion of consumers and remains a major impediment. This reality opens up important market prospects for technological solutions that will contribute to the reliability of the autonomous vehicle. * The Jury for UbiMobility 2017:   Dr. Dragos Maciuca, Technical Director and Senior Technical Leader, Ford Research & Innovation Center, Palo Alto Mr. Drew Winter, Editor-in-Chief, WardsAuto World magazine, Senior Editor, WardsAuto.com, WardsAuto Ms. Françoise Colpron, Group President, Valeo North America Mr. Xavier Mosquet, Senior Partner and Managing Director, Boston Consulting Group Dr. Huei Peng, Director of the University of Michigan Mobility Transformation Center Dr. Gary O’Brien, Global Director of Avanced Engineering, Delphi   ·          Mr. Bret Scott, Head of Silicon Valley Future Technologies, Fiat Chrysler Automobiles   Mr. Ian Simmons, Vice President Business Development and Research and Development, Magna International Mr. Thomas West, Director of PATH - Partners for Advanced Transportation Technology, The University of California - Berkeley   The 8 startups selected for UBIMOBILITY 2017   Acapela Acapela Transport invents speech solutions to vocalize contents with authentic and ultra-natural voices in the transportation market. Over 100 synthetic voices in 34 languages are ready to give a voice to any content producing a natural and pleasant audio result, by turning written input into speech. Our natural voices are available on all main platforms (Cloud, Windows Server, Windows Desktop and mobile, Linux servers and embedded, OSX and iOS, Android…). By mixing two technologies (unit selections and concept-to-speech) we can now generate voices close to a human being in cars but also in other parts of multimodal transport (train, buses, planes…). Chronocam Chronocam is a Paris-based developer of biologically-inspired computer vision sensors and systems for autonomous navigation and IoT applications. Quite simply, its technology, which introduces a new computer vision paradigm based on how the human eye and brain work, significantly improves the performance and power efficiency of how computer vision can be implemented in a wide range of products and applications that improve the convenience and safety of our daily lives. CS Communications & Systèmes CS has developed an innovative technology that improves the efficiency and effectiveness of the Verification and Validation (V&V) process for complex critical systems such as advanced automotive systems.   Its solution permits the generation of scripts of tests of hundreds of lines of code in several seconds, reducing significantly the cost of the tests. Dibotics LiDAR sensors are one of the key components of the Autonomous Car, as they allow for a precise 3D perception of the surroundings. However, they are still too expensive for mass-market adoption and are not giving keen resolution and detailed data compared to, for example, cameras. The real-time software of Dibotics permits the vehicle to know its precise location and to know its environment (obstacles, route, road markings…). Dynamixyz High quality facial analysis middleware which can be applied to a wide range of domains including the automotive industry. We have developed and showcased a car at the CES 2017 in partnership with Visteon which has the abilities to authenticate the driver, track its gaze and do simple expression analysis. This kind of technology is key to the development of ADAS. Neavia Technologies Neavia Technologies has more than 10 years’ experience in devices for ITS (Intelligent Transport Systems): smart cameras, wireless detection of transportation duration and communication vehicle to infrastructure (V2I). All these products for road infrastructure are contributing to better road management, more efficient traffic and to saving more lives. Pertech Pertech Solutions is a French company that designs technological and innovative solutions for Eye Tracking.   Eye Tracking consists of measuring the gaze direction of a subject in order to understand the interaction between the subject and his environment. The innovation is based on the development of high-performance algorithms and software, based solely on image processing techniques, without corneal reflection (without IR), enabling accurate, robust, fast pupillary tracking which is non-intrusive, simple too implement (a few seconds), not influenced by conditions of brightness and without any constraint related to the acquisition equipment (camera). Smart Me Up Computer vision deals with how computers can gain high-level understanding from digital images or videos. It can detect and identify any object in a scene. Vision intelligence goes beyond that definition by understanding the context of the scene and reporting the information (drowsiness detection, car accident detection, pedestrians crossing the road).   At Smart Me Up we bring vision intelligence into cars to create the autonomous car of tomorrow. In fact, it is a light and an affordable solution that can be embedded in any type of camera or OS.   CONTACT   For North America Business France: Mick SALAS: +1 312-327-7710 - michael.salas@businessfrance.fr Omar JANJUA : +1 (416) 903-1258 - omar.janjua@businessfrance.fr                                                 For France: Business France: Clément MOULET: +33 (0)1 40 73 35 31 – clement.moulet@businessfrance.fr Bpifrance: Nathalie POLICE: +33 (0)1 41 79 95 26 - nathalie.police@bpifrance.fr About Business France: Business France is the national agency supporting the international development of the French economy, responsible for fostering export growth by French businesses, as well as promoting and facilitating international investment in France.   Created by the fusion of UbiFrance and the French Agency for International Investments on January 1 st , 2015, Business France counts 1500 collaborators in France and in 70 countries throughout the world.   It promotes France’s companies, business image and nationwide attractiveness as an investment location, and also runs the VIE international internship program . For more information:   www.businessfrance.com     About Bpifrance   : Bpifrance finances businesses through loans, guarantees, and equity during all stages, from the seed phase to transfer and listing on the stock exchange. In partnership with Business France and Coface, Bpifrance accompanies firms developing export activities and provides support for their innovation projects.   Bpifrance offers businesses the benefit of a powerful contact, one who is readily available and able to efficiently respond to their financing needs during For more information: www.bpifrance.com  

Defymed Enters Partnership with Semma Therapeutics

PRESS RELEASE - 13-déc.-2016 18:26:41
Defymed enters partnership with Semma Therapeutics Strasbourg, 12 December 2016 - Defymed, a Strasbourg biotech company specialising in the development of bio-artificial organs, announces a strategic collaboration with Semma Therapeutics, an American biotechnology company specialising in the development of cell therapies for the treatment of diabetes, with the goal of developing of an innovative solution for treating type-1 diabetes. The collaboration is aimed at pre-clinical validation of the MAILPAN® bio-artificial pancreas, a device developed by Defymed, in combination with stem-cell derived differentiated insulin-secreting cells developed by Semma Therapeutics. The combination will be evaluated for effectiveness and safety, at first in vitro and then in an animal model. MAILPAN® is a medical device in the form of a pouch made of bio-compatible polymer comprising semi-permeable membranes that allow glucose, nutriments and oxygen to pass through and hence to reach the pancreatic cells contained in the device, delivering the insulin required to regulate the patient’s blood-sugar level. The membranes are impermeable to the immune system and its antibodies, thereby protecting the patient from rejection of the implanted cells. If successful, the collaboration could be an important step in the fight against the global epidemic of diabetes. Diabetes affects more than 420 million people globally, accounting for around $700B in healthcase spending. Type 1 diabetes alone accounts for $14.9 billion in healthcare costs in the U.S., with 1.25M patients on insulin therapy for the disease. In France, it is estimated that 300 000 people have type-1 diabetes, and 2 000 new cases are diagnosed each year. This therapy would potentially offer the patient an unlimited source of insulin-secreting cells, unlike pancreatic islets which are limited by their availibility. Additionally, the device should obviate the need for immuno-suppression treatment, as its membranes as expected to protect the encapsulated cells from any risk of rejection. The patient would no longer have to think about multiple insulin injections each day, as the MAILPAN® combined with Semma’s cells should deliver the right amount of insulin. Defymed’s autonomous and long-lasting medical device thereby is hoped to substantially reduce the complications connected with diabetes. “Semma Therapeutics’ expertise could represent a major new source for cells usable in our medical device,” said Dr Séverine Sigrist, Founding President of Defymed. “It is vital in Defymed’s strategy to validate our medical device with what are currently the most promising cells. We believe the approach developed by Semma is the most advanced worldwide. Everything points to our collaboration being a great success. So I welcome this partnership, which looks very promising indeed!” “Defymed offers one of the most promising options available today in terms of a third party immunoprotective device,” said Robert Millman, CEO of Semma Therapeutics. “We’re excited for the collaboration and look forward to the results.” This exemplary cooperation was recognized as “Best innovative trial design leading to a quicker and better therapeutic outcome” at the MedStartup - Galien Award event on 27 October 2016 in New York. For Defymed, the collaboration follows just six months after concluding a financial agreement for half a million dollars with the JRDF, a global foundation that funds research into treatment for type-1 diabetes. Defymed also has the support and accompaniment of Business France for its development in the United States. The Strasbourg biotech company is keen to become established in this important market in the very near future. About Defymed Defymed, a spin-off of the European centre for the study of diabetes CeeD (Centre Européen d’Étude du Diabète), is a biotechnology company set up in March 2011; it specialises in the design and development of innovative bio-artificial medical devices. Defymed’s initial focus is on developing an application for treating type 1 diabetes. The first product it has designed is MAILPAN©, an implantable bio-artificial pancreas intended to re-establish the normal production of insulin in type 1 diabetics. The MAILPAN© prototype was produced with financial support from the European Commission. The company owns exclusive technology that enables it to produce medical devices for use in other therapeutic applications. Defymed’s strength lies in its network of French and international partners. For more information, please visit www.defymed.com. About Semma Therapeutics Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients. Work in the laboratory of Professor Douglas Melton led to the discovery of a method to generate billions of functional, insulin-producing beta cells in the laboratory. This breakthrough technology has been exclusively licensed to Semma Therapeutics for the development of a cell-based therapy for diabetes. Ongoing research at Semma Therapeutics is focused on combining these proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. Semma Therapeutics is working to bring new therapeutic options to the clinic and improve the lives of patients with diabetes. The company is headquartered in Cambridge, MA. For more information, visit www.semma-tx.com. COMMUNIQUE DE PRESSE DEFYMED 8 Avenue Dante 67000 Strasbourg - France Tel. +33 (0)3 90 41 04 46 www. defymed .com Further information and visuals available on request from our press service: OXYGEN | Press contacts 2 Rue d’Ingwiller - 67000 Strasbourg [France] Elise Cordier +33 (0)3 67 22 03 25 - elisec@oxygen-rp.com Jérémie Lotz +33 (0)6 11 25 48 05 - jlotz@oxygen-rp.com  

MEDSTARTUP PARTNERING DAY 2016

PRESS - 03-oct.-2016 21:40:13
MEDSTARTUP PARTNERING DAY 2016 Details Start: October 27, 2016 End: October 27, 2016 Event Category: Partner Event Website: medstartup.galienfoundation.org/wp Organizer: Galien Foundation & Business France Phone: 212 400 2168 Website : www.galienfoundation.org Sponsors: Medidata & BIO Registration: Free for Early Birds Venue: Alexandria Center for Life Sciences, 450 E 29th St, New York, NY 10016 Business France & The Galien Foundation are pleased to invite you to the Medstartup Partnering Day to: NETWORK with +250 Leaders in the EHealth/Pharma/Medtech industries SOURCE INNOVATION Meet with +50 innovative French Health Tech companies EXPAND Identify strategic partners to access to the European market       This year we will count with the presence of Bernard Poussot, Director, Roche Holding, Former President & CEO, Wyeth -   Joel Marcus, Founder & CEO, Alexandria Real Estate Equities. - Roch DOLIVEUX - Honorary CEO, UCB -Mikael DOLSTEN - Global R&D President, Pfizer -Jean-Pierre GARNIER – Former CEO, GSK -Franz HUMER - Former CEO, Roche -François MAISONROUGE - Senior Managing Director, EvercorePartners -Paul STOFFELS - Chief Scientific Officer, Johnson and Johnson -Elias ZERHOUNI - Global R&D President, Sanofi Key Figures & Facts: +20 New EU-US collaborations per year +65% of C-Levels +550 BtoB Meetings +250  Leaders Every year, MedStartUp Program organized by the Galien Foundation & Business France encourages and rewards transatlantic partnerships in the Healthcare industries. The MedstartUp will bring together:   55 highly innovative French companies in the healthcare industry and 250 American leaders in the Pharma/MedTech /Digital Health industries. For further information, visit our website medstartup.galienfoundation.org/wp

French Tech Ticket - Season 2: Submit Your Startup Project Today!

PRESS - 27-juil.-2016 16:07:28
  French Tech Ticket - season 2: Submit your startup project today! Apply to the global competition and get a chance to grow your startup in a booming ecosystem! 70 selected startups will be awarded a full package of benefits including a 45,000 Euros prize money, 1-year incubation, a dedicated masterclass programme… and much more! Your startup project is in BioTech, Mobile/Web, Big Data, FinTech, Social Innovation or any other industry? With over 40 partner incubators all over France to choose from, you’ll find the right one to lead you to success! The competition is open to entrepreneurs from all over the world and there’s only one month left to apply! Check out the French Tech Ticket website for more information and apply online before August 24 th ! www.frenchtechticket.com  

PRESS: Defymed Receives Support from JDRF to Fight Type 1 Diabetes

PRESS - 13-juil.-2016 00:41:48
Defymed Receives Support from JDRF to Fight Type 1 Diabetes JDRF will contribute up to $500,000 in funds to finance preclinical studies on the MAILPAN ® bioartificial pancreas NEW YORK, July XX 2016 – Defymed, a French biotechnology company specializing in the development of bioartificial organs today announced a partnership with JDRF, the leading global organization funding type 1diabetes (T1D) research. This new investment gives Defymed the opportunity to advance its pre-clinical studies in order to demonstrate the MAILPAN ® immunoprotection properties, safety and function. This is an essential step before beginning the clinical trials on humans. " JDRF is known as the number-one worldwide public foundation fighting type 1 diabetes. We are more than honored to be working with them for the necessary pre-clinical tests before starting the MAILPAN® clinical phase ," explains Dr. Séverine Sigrist, CEO of Defymed. " More than financial support, JRDF brings to us considerable visibility within the U.S. market and also provides strategic support in regards to finding a solution to encapsulating insulin-secreting cells to derive the benefits offered by this therapy to patients suffering from type 1 diabetes." With this support, Defymed will move significantly forward with clinical trials in humans. This new project, scheduled to take up to 24 months, will be conducted simultaneously as other research and development programs currently in progress at Defymed. It will allow Defymed to test the MAILPAN® bioartificial pancreas designed for type 1 diabetics through the preclinical phase in order to: - Strengthen the results on MAILPAN ® ’s immunoprotection properties in combination with insulin-secreting cells. - Confirm collected data on the MAILPAN ®’s functionality and safety , also in combination with insulin-secreting cells. MAILPAN® , a disruptive technology for a better life Almost 25 million people around the world suffer from type 1 diabetes. MAILPAN®, an implantable bioartificial pancreas, is a serious alternative to existing treatments. This medical device is designed to restore normal and continuous insulin production in diabetic patients. Implanted in the abdomen, it takes the shape of a pouch containing insulin-secreting cells. The potential of MAILPAN® will bring numerous advantages in comparison to current treatments (e.g., no anti-rejection drugs in case of pancreatic transplants, absence of multiple insulin injections per day). The bioartificial pancreas’ underlying principle’ is to encapsulate insulin-secreting cells between membranes impermeable to the immune system, but permeable enough for oxygen, nutrients, glucose and insulin. A bioartificial pancreas must fulfill three prerequisite functions: to protect transplanted cells from the patient immune system, to protect the patient from transplanted cells, and to maximize the function of the transplanted cells. The goal of the project is to ensure the function and safety of the medical device, utilizing Defymed’s expertise in the biomaterial and cell transplant , as well as preclinical validation and non-invasive imaging technologies. This strategic step for Defymed confirms the therapeutic interest of the MAILPAN® and will generate preclinical data that is absolutely necessary to build strong regulatory documentation for the MAILPAN® , associated with insulin-secreting cells, which will be necessary to bring it to clinical trials in humans. "JDRF is excited to announce its support of Defymed as it seeks preclinical validation of its MAILPAN® device, a project which is well aligned with JDRF’s Beta Cell Replacement strategy," said Derek Rapp, JDRF president and CEO. "By funding this type of research, we firmly believe we are moving one step closer to our goal of creating a world without type 1 diabetes. Major challenges for Alsatian biotech JRDF support appears as a testament of confidence and represents an important opportunity for Defymed to make significant strides in the biotech world. It will indeed bring more visibility and awareness to French biotech on an international platform. From a strategic standpoint, this financial support will also allow Defymed to pursue its development in Europe but also to prepare its entry in its new target market, the U.S. Defymed has also become a member of the encapsulation consortium, a key JDRF initiative. Its goal is to accelerate the development of a bioartificial pancreas for individuals living with type 1 diabetes. For the complete press release, click the link below    

7th French Pavilion at Suppliers’ Day

Pauline MARIE - 07-avr.-2016 00:18:38
  We look forward to greeting you for the launch of the 7th edition of the French Pavilion on Suppliers’ Day. French cosmetics ingredients manufacturers and testing companies will present their latest innovations at the show, on May 10th and 11th in Edison, NJ. BUSINESS FRANCE is proud to introduce this year’s Pavilion’s 10 exhibitors: •ALDIVIA, •AGRIMER, •BIOALTERNATIVES, •CIMAPREM, •DERMSCAN, •EOTECH, •INTERPOLYMER, •MINASOLVE, •PACIFIQUE SUD COSMETIQUE, •TOTAL FLUIDES. For more info about the Pavilion and the companies, please visit our dedicated website . To get the most up to date information, follow us on Twitter @BF_beautycare and on our Facebook!

Meet Alizé RP - Business France Sponsor for the Upcoming BIO 2016 Convention

PRESS - 28-mars-2016 17:08:34
  Alize RP is a multilingual PR agency  (French, English, German and Spanish) specialized in Innovation with 4 domains of expertise: Biotech / Medtech; Healthcare / Cosmetics; Cleantech; and FinTech / Digital. Alize PR represents innovative businesses (start-ups, high-growth companies, pre- and post-exit phases) and private or listed companies in emerging markets, as well as industry bodies and state-owned organisms. We offer a wide range of services including : global communications campaigns ; digital campaigns; media relations in France, Europe and the US; press document development; crisis communication strategy; events ; and Graphic Design. We are not just experts in PR – we are also experts in a specific sector: Innovation. Our sharp focus means that we know all the key media, institutional and industry players & stakeholders in this specific market. Based on our in-depth market & segment knowledge, we are able to offer a tailor-made solution to each of our clients.        
About us
Arnaud Leretour: "Welcome to Business France North America!" We assist French companies who want to export in North America, and North American companies who want to invest in France. Our team has both the knowledge and the experience to facilitate BtoB trade relations between the three countries. With offices and branches in New York, Boston, Toronto, Montréal, Atlanta, Detroit, Chicago, Houston, Vancouver and San Francisco, Business France North America is present from coast to coast. Close to 100 Business France experts focus on the following sectors: - Agrotech (wine, spirits, beer, beverages, food, and equipments for the agricultural and food industry) - Industry & clean tech (public works & transportation, energy & clean techs, industry) - Art de vivre & healthcare (biotechnologies, cosmetics, healthcare, fashion, luxury, culture, sport, home decor and tourism) - Tech & services (new technologies, retail and services, inn

READ MORE

Facebook
Press area & Media Gallery
List of last comments